...
首页> 外文期刊>Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer >PI3K-AKT-mTOR pathway: Description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer
【24h】

PI3K-AKT-mTOR pathway: Description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer

机译:PI3K-AKT-mTOR途径:癌症的描述,治疗进展,耐药性,预测/预后生物标志物和治疗应用

获取原文
获取原文并翻译 | 示例

摘要

Among many cancer cells signaling pathways, PI3K-AKT-mTOR plays a major role in growth, proliferation and cellular survival. This is a complex pathway activated either by an extracellular way (receptors with tyrosine kinase activity) or by an intracellular way with transformed or overexpressed proteins involved in the signal transduction. To date, there are many applications of mTOR inhibitors in oncology with an expanding development rapidly. However, resistances appear to mTOR inhibitors which lead to 2nd generation mTOR inhibitors development. A better knowledge of predictive and prognostic biomarkers will allow to specify the group of patients who may benefit from these treatments and help to the choice.
机译:在许多癌细胞信号传导途径中,PI3K-AKT-mTOR在生长,增殖和细胞存活中起主要作用。这是一种复杂的途径,可以通过细胞外方式(具有酪氨酸激酶活性的受体)激活,也可以通过细胞内方式激活,并通过参与信号转导的转化或过度表达的蛋白质激活。迄今为止,mTOR抑制剂在肿瘤学中有许多应用,并且发展迅速。然而,对mTOR抑制剂的抗药性似乎导致了第二代mTOR抑制剂的发展。更好地了解预测性和预后性生物标志物将有助于确定可能从这些治疗中受益并有助于选择的患者组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号